DelveInsight's 'Antiphospholipid Syndrome (APS) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Antiphospholipid Syndrome (APS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Study Period: 2017-2030
The DelveInsight Antiphospholipid Syndrome (APS) epidemiology report gives a thorough understanding of the Antiphospholipid Syndrome (APS) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Antiphospholipid Syndrome (APS) in the US, Europe, and Japan. The report covers the detailed information of the Antiphospholipid Syndrome (APS) epidemiology scenario in seven major countries (US, EU5, and Japan).
The Antiphospholipid Syndrome (APS) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Antiphospholipid Syndrome (APS) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Antiphospholipid Syndrome (APS) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The Antiphospholipid Syndrome (APS) epidemiology covered in the report provides historical as well as forecasted Antiphospholipid Syndrome (APS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Antiphospholipid Syndrome (APS) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
1. Key Insights
2. Executive Summary of Antiphospholipid Syndrome (APS)
3. Antiphospholipid Syndrome (APS): Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Antiphospholipid Syndrome (APS) Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Antiphospholipid Syndrome (APS) Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Antiphospholipid Syndrome (APS) Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Antiphospholipid Syndrome (APS) Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Antiphospholipid Syndrome (APS) Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Antiphospholipid Syndrome (APS) Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Antiphospholipid Syndrome (APS) Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Antiphospholipid Syndrome (APS) Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Antiphospholipid Syndrome (APS) Treatment and Management
6.2. Antiphospholipid Syndrome (APS) Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
Table 1 Antiphospholipid Syndrome (APS) Epidemiology in 7MM (2017-2030)
Table 2 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in 7MM (2017-2030)
Table 3 Antiphospholipid Syndrome (APS) Epidemiology in the United States (2017-2030)
Table 4 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 Antiphospholipid Syndrome (APS) Epidemiology in Germany (2017-2030)
Table 6 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 Antiphospholipid Syndrome (APS) Epidemiology in France (2017-2030)
Table 8 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in France (2017-2030)
Table 9 Antiphospholipid Syndrome (APS) Epidemiology in Italy (2017-2030)
Table 10 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 Antiphospholipid Syndrome (APS) Epidemiology in Spain (2017-2030)
Table 12 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 Antiphospholipid Syndrome (APS) Epidemiology in the United Kingdom (2017-2030)
Table 14 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Table 15 Antiphospholipid Syndrome (APS) Epidemiology in Japan (2017-2030)
Table 16 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 1 Antiphospholipid Syndrome (APS) Epidemiology in 7MM (2017-2030)
Figure 2 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in 7MM (2017-2030)
Figure 3 Antiphospholipid Syndrome (APS) Epidemiology in the United States (2017-2030)
Figure 4 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 Antiphospholipid Syndrome (APS) Epidemiology in Germany (2017-2030)
Figure 6 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 Antiphospholipid Syndrome (APS) Epidemiology in France (2017-2030)
Figure 8 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 Antiphospholipid Syndrome (APS) Epidemiology in Italy (2017-2030)
Figure 10 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 Antiphospholipid Syndrome (APS) Epidemiology in Spain (2017-2030)
Figure 12 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 Antiphospholipid Syndrome (APS) Epidemiology in the United Kingdom (2017-2030)
Figure 14 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Figure 15 Antiphospholipid Syndrome (APS) Epidemiology in Japan (2017-2030)
Figure 16 Antiphospholipid Syndrome (APS) Diagnosed and Treatable Cases in Japan (2017-2030)
*The table of contents is not exhaustive; will be provided in the final report